BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jäntti MH, Putula J, Turunen PM, Näsman J, Reijonen S, Lindqvist C, Kukkonen JP. Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling. Mol Pharmacol 2013;83:621-32. [PMID: 23233488 DOI: 10.1124/mol.112.080523] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Brodie JS, Di Marzo V, Guy GW. Polypharmacology Shakes Hands with Complex Aetiopathology. Trends Pharmacol Sci 2015;36:802-21. [PMID: 26434643 DOI: 10.1016/j.tips.2015.08.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
2 Ahmadi-soleimani SM, Azizi H, Gompf HS, Semnanian S. Role of orexin type-1 receptors in paragiganto-coerulear modulation of opioid withdrawal and tolerance: A site specific focus. Neuropharmacology 2017;126:25-37. [DOI: 10.1016/j.neuropharm.2017.08.024] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
3 Kukkonen JP. Lipid signaling cascades of orexin/hypocretin receptors. Biochimie 2014;96:158-65. [PMID: 23810911 DOI: 10.1016/j.biochi.2013.06.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
4 Jäntti MH, Mandrika I, Kukkonen JP. Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors. Biochem Biophys Res Commun 2014;445:486-90. [PMID: 24530395 DOI: 10.1016/j.bbrc.2014.02.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
5 Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Front Neurosci 2014;8:57. [PMID: 24834023 DOI: 10.3389/fnins.2014.00057] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
6 Laguerre A, Hauke S, Qiu J, Kelly MJ, Schultz C. Photorelease of 2-Arachidonoylglycerol in Live Cells. J Am Chem Soc 2019;141:16544-7. [PMID: 31560527 DOI: 10.1021/jacs.9b05978] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
7 Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP. Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals (Basel) 2017;10:E79. [PMID: 28991183 DOI: 10.3390/ph10040079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
8 Milligan G. The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization. Mol Pharmacol 2013;84:158-69. [PMID: 23632086 DOI: 10.1124/mol.113.084780] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 9.3] [Reference Citation Analysis]
9 Kukkonen JP. G-protein inhibition profile of the reported Gq/11 inhibitor UBO-QIC. Biochem Biophys Res Commun 2016;469:101-7. [PMID: 26614908 DOI: 10.1016/j.bbrc.2015.11.078] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
10 Cristino L, Imperatore R, Di Marzo V. Techniques for the Cellular and Subcellular Localization of Endocannabinoid Receptors and Enzymes in the Mammalian Brain. Cannabinoids and Their Receptors. Elsevier; 2017. pp. 61-98. [DOI: 10.1016/bs.mie.2017.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Vitale RM, Iannotti FA, Schiano Moriello A, Tunisi L, Piscitelli F, Savopoulos R, Cristino L, De Petrocellis L, Amodeo P, Gray R, Di Marzo V. Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation. Biomolecules 2021;11:1134. [PMID: 34439801 DOI: 10.3390/biom11081134] [Reference Citation Analysis]
12 Rinne MK, Leino TO, Turku A, Turunen PM, Steynen Y, Xhaard H, Wallén EA, Kukkonen JP. Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26. European Journal of Pharmacology 2018;837:137-44. [DOI: 10.1016/j.ejphar.2018.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
13 Putula J, Pihlajamaa T, Kukkonen JP. Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery. Br J Pharmacol 2014;171:5816-28. [PMID: 25132134 DOI: 10.1111/bph.12883] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
14 Coleman P, de Lecea L, Gotter A, Hagan J, Hoyer D, Kilduff T, Kukkonen JP, Porter R, Renger J, Siegel JM, Sutcliffe G, Upton N, Winrow CJ. Orexin receptors in GtoPdb v.2021.3. IUPHAR BPS Guide Pharm CITE 2021;2021. [PMID: 34927075 DOI: 10.2218/gtopdb/f51/2021.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Coccurello R, Maccarrone M. Hedonic Eating and the "Delicious Circle": From Lipid-Derived Mediators to Brain Dopamine and Back. Front Neurosci 2018;12:271. [PMID: 29740277 DOI: 10.3389/fnins.2018.00271] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
16 Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 2014;171:314-31. [PMID: 23902572 DOI: 10.1111/bph.12324] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 13.0] [Reference Citation Analysis]
17 Berrendero F, Flores Á, Robledo P. When orexins meet cannabinoids: Bidirectional functional interactions. Biochemical Pharmacology 2018;157:43-50. [DOI: 10.1016/j.bcp.2018.08.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
19 Sidibeh CO, Pereira MJ, Lau Börjesson J, Kamble PG, Skrtic S, Katsogiannos P, Sundbom M, Svensson MK, Eriksson JW. Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance. Endocrine 2017;55:839-52. [PMID: 27858284 DOI: 10.1007/s12020-016-1172-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
20 Nagappan A, Shin J, Jung MH. Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications. Int J Mol Sci 2019;20:E2109. [PMID: 31035653 DOI: 10.3390/ijms20092109] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
21 Imperatore R, Palomba L, Morello G, Spiezio AD, Piscitelli F, Marzo VD, Cristino L. Formation of OX-1R/CB 1 R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. Pharmacological Research 2016;111:600-9. [DOI: 10.1016/j.phrs.2016.07.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
22 Kukkonen JP. Orexin/Hypocretin Signaling. Curr Top Behav Neurosci 2017;33:17-50. [PMID: 27909990 DOI: 10.1007/7854_2016_49] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
23 Flores A, Maldonado R, Berrendero F. Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Front Neurosci 2013;7:256. [PMID: 24391536 DOI: 10.3389/fnins.2013.00256] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
24 Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol 2014;171:294-313. [PMID: 23848055 DOI: 10.1111/bph.12296] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
25 Cristino L, Palomba L, Di Marzo V. New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism. Int J Obes Suppl 2014;4:S26-30. [PMID: 27152162 DOI: 10.1038/ijosup.2014.8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
26 Eldeeb K, Leone-Kabler S, Howlett AC. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function. J Basic Clin Physiol Pharmacol 2016;27:311-22. [PMID: 27089415 DOI: 10.1515/jbcpp-2015-0096] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
27 Ge D, Odierna GL, Phillips WD. Influence of cannabinoids upon nerve-evoked skeletal muscle contraction. Neuroscience Letters 2020;725:134900. [DOI: 10.1016/j.neulet.2020.134900] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]